J&J experiences long-term QUASAR information for Tremfya in ulcerative colitis
Johnson & Johnson (J&J) has reported new findings from the QUASAR long-term extension research of Tremfya (guselkumab) for ulcerative colitis (UC).
The outcomes highlighted that the dual-acting monoclonal antibody Tremfya maintained endoscopic, histological and scientific remission via week 140 in adults with reasonably to severely energetic UC.
Uncover B2B advertising that delivers
Mix enterprise intelligence and editorial excellence to succeed in engaged professionals throughout 36 main media platforms.
Extra info
The Section IIb/III, double-blind, randomized, multicenter, placebo-controlled research is designed to evaluate the protection and efficacy of Tremfya in adults.
This consists of sufferers who haven’t responded to or had been illiberal to standard therapies similar to thiopurines or corticosteroids, earlier biologics together with tumor necrosis issue (TNF) antagonists or vedolizumab, and/or Janus kinase inhibitors (JAK inhibitors).
QUASAR included a Section IIb multi-dose induction research, a confirmatory Section III induction research, and a randomized Section III upkeep discontinuation research.
Within the Section III induction portion, sufferers obtained 200 mg guselkumab or placebo through IV infusion at weeks 0, 4, and eight.
At week 140, 80.8% of these receiving guselkumab achieved scientific remission. Histoendoscopic mucosal enchancment was recorded in 78.6% of sufferers and 53.6% achieved endoscopic remission.
Roughly 89% of eligible members accomplished remedy via week 140. Practically all topics in scientific remission at the moment level had been freed from corticosteroids for not less than eight weeks.
Of these in remission at week 44, 87.5% remained in remission via week 140. Efficacy remained constant no matter prior use of biologics or JAK inhibitors, and no new security considerations had been recognized.
Esi Lamousé-Smith, J&J vp and chief in immunology-gastroenterology, stated, “These findings spotlight the endoscopic outcomes that may be achieved with Tremfya, elevating expectations about what is feasible for sufferers with ulcerative colitis. Sufferers who obtain endoscopic remission expertise fewer flares and are much less prone to want steroids or surgical procedure over time.”
In January 2026, J&J’s Caplyta (lumateperone) together with antidepressants almost doubled the possibility of remission after six weeks, and the profit was maintained for greater than six months in sufferers identified with main depressive dysfunction (MDD).
